Short communication · 30 Sep 2023
Review articlePublished 30 Dec 2015
The Role of Coffee in the Therapy of Parkinson's Disease
The USF-Health Byrd’s Alzheimer’s Center and Research Institute, Tampa, FL, USA; The College of Pharmacy at University of South Florida, Tampa, FL, USA; Department of Neurology at Morsani College of Medicine, Tampa, FL, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Active compounds in coffee have been reported to possess therapeutic effects in treating Parkinson’s disease (PD). PD is a neurological degenerative disorder affecting millions of people around the world and to this day, there is no known cure or effective method to prevent or delay the disease progress. The most effective drug being used to treat symptoms of PD is L-3,4-dihydroxyphenyalanine (L-DOPA). However, chronic use of L-DOPA diminishes its effectiveness as well as inducing dyskinesia. Current studies have shown that coffee consumption enhances the effects of L-DOPA and has a preventative role in both the onset and progression of PD. Coffee also has been reported to increase the plasma levels of granulocyte colony-stimulating factors (G-CSF), a protein that also possesses neuroprotective functions. G-CSF may be used in combination treatments with L-DOPA and coffee to synergize their function for treating PD. The underlying processes are not fully understood as to how coffee interacts with both L-DOPA and G-CSF in PD models. This review attempts to provide a possible mechanism for these interactions. Understanding the metabolic interactions between coffee, L-DOPA, and G-CSF may shed light on new therapeutic treatments to treat PD.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 31 Aug 2018
The role of sphingosine kinase-1 and sphingosine-1-phosphate signaling in experimental model of Parkinson disease: The novel targets in therapy
Conference abstract · 3 Sep 2021
The Electroactive Signal for the Tau Peptide- Part 2: Neuromolecular Imaging (NMI): A LIVE Nanotechnology for Alzheimer, Parkinson and Epilepsy Disease: The BRODERICK PROBE� Biosensor Images the Effects of the Pharmaceutical, L-DOPA, in Long-Term Neurodegeneration in Parkinson Subjects
Conference abstract · 18 May 2018
Pre-Clinical Investigation of Combo Drug Containing L-Dopa And Ceftriaxone in Mouse Models Of Parkinson’s Disease
Conference abstract · 25 Sep 2017
Impact of vinpocetine on the therapeutic effectiveness of L-DOPA using rat model of Parkinson's disease
More from this journal
The newest in Journal of Alzheimers Disease & Parkinsonism.
Commentary · 8 Jun 2026
Cognitive Concerns: The Side Effects of Surgery in Alzheimer's Patients
Perspective · 8 Jun 2026
Oxidative Stress and Its Role in Neuronal Degeneration: Mechanisms and Implications
Commentary · 8 Jun 2026
Understanding the Pathophysiology of Prion-Induced Dementia
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Alzheimers Disease & Parkinsonism
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Andrew Tran”
- BylineArticles whose byline prints “Cecilia Yijun Zhang”
- BylineArticles whose byline prints “Chuanhai Cao”
